A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain. In the Phase 3 trial, Lilly tested the two strongest doses of retatrutide, which works on three different hormones that affect appetite and metabolism, in adults who were overweight or had obesity and also had knee osteoarthritis, but did not have diabetes. When used along with diet and exercise, the drug led to major weight loss and also helped reduce pain and improve how well people could move. Spec...

6 days ago

On HALO